Journal: Leukemia

Article Title: Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell/histiocyte-rich large B-cell lymphoma identified by whole genome sequencing

doi: 10.1038/s41375-025-02679-3

Figure Lengend Snippet: A , B Overview of the observed breakpoints in case 3 and case 4 using IGV plots. C Breakpoint-spanning Sanger sequence obtained from the rearrangement in case 3. D Breakpoint-spanning Sanger sequence obtained from the rearrangement in case 4. E Immunofluorescence double staining of BCL6 (red) and CD74 (green) with DAPI counterstaining showing strong nuclear expression of BCL6 in the LP cells of case 3 and weak membrane bound expression of CD74 (arrows). F Immunofluorescence double staining of BCL6 (red) and CD74 (green) with DAPI counterstaining showing strong nuclear expression of BCL6 in the LP cells of case 4 with absence of CD74 expression (arrows). Preserved membrane bound expression of CD74 is observed in non-tumor cells. G Schematic representation of rearrangement in case 3 using BrassVis .

Article Snippet: Antibodies to BCL6 (clone m7211, Agilent-DAKO, Santa Clara, USA) and CD74 (HPA-010592, Atlas antibodies, Stockholm, Sweden) were applied at dilutions of 1:20 and 1:250, respectively.

Techniques: Sequencing, Immunofluorescence, Double Staining, Expressing, Membrane

Journal: Pharmaceuticals

Article Title: Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

doi: 10.3390/ph16040590

Figure Lengend Snippet: Antibody–Drug Conjugates in Clinical Trials in Multiple Myeloma.

Article Snippet: 8 , STRO-001 , IgG1 , A p-azido-methyl-phenylalanine (pAMF)-containing anti-CD74 aglycosylated human IgG1; maytansinoid conjugated to two sites , A non-cleavable dibenzocyclooctyne linker , Sutro Biopharma, Inc. South San Francisco, CA, U.S..

Techniques: Conjugation Assay, Derivative Assay, Binding Assay, Recombinant